Mithra Pharmaceuticals SA News - 1TM

FeaturedFreedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent

Mithra reports full year 2023 financial results

Mithra reports full year 2023 financial results Mithra reports full year 2023 financial results Revenues were EUR 40.2 million, down from...

Mithra announces changes to its executive management

Mithra announces changes to its executive management Mithra announces changes to its executive management Liege, Belgium, 05 March 2024 –...

Mithra initiates monetization process, receives bridge loan from existing lenders

Mithra initiates monetization process, receives bridge loan from existing lenders Mithra initiates monetization process, receives bridge...

DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase

DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase DONESTA®...

Mithra sells shares in Mayne Pharma

Mithra sells shares in Mayne Pharma Mithra sells shares in Mayne Pharma Mithra sold all 4,221,815 shares it held in Mayne Pharma...

Mithra updates on cash position

Mithra updates on cash position Mithra updates on cash position Mithra's current cash of EUR 6.5 million is expected to cover its...

Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel

Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel Mithra and Rafa Laboratories sign...

Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients

Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients...

Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial

Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3...

Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China

Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China Mithra and Gedeon Richter...

Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States

Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States Mithra receives guidance...

Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam

Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam...

Mithra’s NEXTSTELLIS® granted additional patent in the United States

Mithra’s NEXTSTELLIS® granted additional patent in the United States Mithra’s...

Mithra releases invitation to its extraordinary securities holders’ meeting

Mithra releases invitation to its extraordinary securities holders’ meeting Mithra releases invitation to its extraordinary...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Mithra Pharmaceuticals SA (1TM)

Empower your portfolio: Real-time discussions and actionable trading ideas.

1TM News

FeaturedFreedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent

Mithra reports full year 2023 financial results

Mithra announces changes to its executive management

Mithra initiates monetization process, receives bridge loan from existing lenders

DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase

Mithra sells shares in Mayne Pharma

Mithra updates on cash position

Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel

Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients

Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial

Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China

Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States

Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam

Mithra’s NEXTSTELLIS® granted additional patent in the United States

Mithra releases invitation to its extraordinary securities holders’ meeting

1TM Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Mithra Pharmaceuticals SA (1TM) News

Mithra Pharmaceuticals SA (1TM)

Empower your portfolio: Real-time discussions and actionable trading ideas.

1TM News

FeaturedFreedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent

Mithra reports full year 2023 financial results

Mithra announces changes to its executive management

Mithra initiates monetization process, receives bridge loan from existing lenders

DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase

Mithra sells shares in Mayne Pharma

Mithra updates on cash position

Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel

Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients

Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial

Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China

Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States

Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam

Mithra’s NEXTSTELLIS® granted additional patent in the United States

Mithra releases invitation to its extraordinary securities holders’ meeting

1TM Discussion

Your Recent History